Important Data on COVID-19 Profile in Africa
AIDCO
2 other identifiers
observational
574
1 country
2
Brief Summary
The purpose of this study is to Understand the natural history of Coronavirus 2019 (COVID-19) infection to better define the period of infectiousness and transmissibility and to establish biobanks of COVID-19 blood and mucosal samples.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2020
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2020
CompletedFirst Submitted
Initial submission to the registry
October 16, 2020
CompletedFirst Posted
Study publicly available on registry
April 19, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2022
CompletedJuly 19, 2022
April 1, 2021
1.4 years
October 16, 2020
July 18, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
clinical and biological parameters of COVID-19
Infection and disease progression - Pattern of virus transmission
14 days
SARS-CoV-2 transmissibility
proportion of household contact who will become positive for SARS-COV2 using PCR
14 days
Study Arms (2)
Index cases
Patients infected by SARS-Cov2 Polymerase Chain Reaction (PCR) and hospitalized in a referral center for COVID-19 .
Households cases
Household contacts of SARS-Cov2 hospitalized COVID-19 patients.
Eligibility Criteria
The study population will consist of volunteer COVID-19 patients hospitalized in referral center for COVID-19 care as well as the household contacts of these hospitalized COVID-19 patients in Gabon, Senegal and Ethiopia.
You may qualify if:
- Molecular (PCR) confirmed COVID-19 patients hospitalized in referral centers,
- Household contacts of hospitalized COVID-19 patient,
- Provided signed informed consent.
You may not qualify if:
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Centre de Recherche Médicale de Lambarénélead
- European and Developing Countries Clinical Trials Partnership (EDCTP)collaborator
- Leiden University Medical Centercollaborator
- Institut de recherche en santé de surveillance épidémiologique et de formationcollaborator
- Université des Sciences de la Santécollaborator
- Armauer Hansen Research Institute, Ethiopiacollaborator
- Universität Tübingencollaborator
Study Sites (2)
Centre de Recherches Médicales de Lammbaréné
Lambaréné, Moyen-Ogooué Province, 1437, Gabon
Centre de Recherches Médicales de Lambréné
Lambaréne, Gabon
Biospecimen
Nasopharyngeal mucosal Blood Urine Stool
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ayôla Akim ADEGNIKA
Centre de Recherches Médicales de Lambaréné
- PRINCIPAL INVESTIGATOR
Marielle BOUYOU-AKOTET
Université des Sciences de Santé
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 16, 2020
First Posted
April 19, 2021
Study Start
August 1, 2020
Primary Completion
December 31, 2021
Study Completion
March 1, 2022
Last Updated
July 19, 2022
Record last verified: 2021-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- 2 years
Results from our COVID-19 AFRICA, AIDCO, project will be published in peer reviewed journals, seeking rapid and open access publication. This will be done as fast and widely as possible. Results will also be submitted and presented in any national, regional and international scientific meetings and congresses dedicated to COVID-19 online or face to face if, permitted. Before submission for publication or presentation, the review process outlined in the Consortium Agreement and agreed upon by all partners will be followed and care will be taken with respect to intellectual property protection.